⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
Form 8-K
sec.gov
AIM
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
globenewswire.com
AIM
AiM Medical Robotics Awarded $2 Million National Cancer Institute Grant to Advance MRI-Guided Robotic Treatment of Brain Cancer
globenewswire.com
AIM
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
globenewswire.com
AIM
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
globenewswire.com
AIM
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
globenewswire.com
AIM
Form 8-K
sec.gov
AIM